Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition-Reference-Cited by-同舟云学术

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

Published:2011-06-26 Issue:7 Volume:17 Page:875-882
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Johnson Neil,Li Yu-Chen,Walton Zandra E,Cheng Katherine A,Li Danan,Rodig Scott J,Moreau Lisa A,Unitt Christine,Bronson Roderick T,Thomas Huw D,Newell David R,D'Andrea Alan D,Curtin Nicola J,Wong Kwok-Kin,Shapiro Geoffrey I

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.2377.pdf

Reference36 articles.

1. Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770–1783 (2006).

2. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153–166 (2009).

3. Hochegger, H. et al. An essential role for Cdk1 in S phase control is revealed via chemical genetics in vertebrate cells. J. Cell Biol. 178, 257–268 (2007).

4. Ira, G. et al. DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1. Nature 431, 1011–1017 (2004).

5. Jazayeri, A. et al. ATM- and cell cycle–dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8, 37–45 (2006).

Cited by 243 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of Potential Inhibitors of CDK1 by Integrating Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation Studies, and Evaluation of Their Inhibitory Activity;ACS Omega;2024-09-13

2. Star wars against leukemia: attacking the clones;Leukemia;2024-09-02

3. Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer;Frontiers in Oncology;2024-08-02

4. Exploration of Potential Cyclin-dependent Kinases and their Inhibitors to Combat Abnormal Signalling and Cancer;Current Signal Transduction Therapy;2024-07

5. Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group;Frontiers in Oncology;2024-06-04